 | Up a level |
le Roux, Carel W, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Lau, David CW, Van Gaal, Luc, Ortiz, Rafael Violante, Wilding, John PH 
ORCID: 0000-0003-2839-8404, Skjoth, Trine V, Manning, Linda Shapiro et al (show 2 more authors)
(2017)
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
LANCET, 389 (10077).
pp. 1399-1409.
Fujioka, Ken, O'Neil, Patrick M, Davies, Melanie, Greenway, Frank, Lau, David CW, Claudius, Birgitte, Skjoth, Trine Vang, Jensen, Christine Bjorn and Wilding, John PH ORCID: 0000-0003-2839-8404
(2016)
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
OBESITY, 24 (11).
pp. 2278-2288.
O'Neil, Patrick M, Aroda, Vanita R, Astrup, Arne, Kushner, Robert, Lau, David CW, Wadden, Thomas A, Brett, Jason, Cancino, Ana-Paula and Wilding, John PH ORCID: 0000-0003-2839-8404
(2017)
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
DIABETES OBESITY & METABOLISM, 19 (11).
pp. 1529-1536.